Cargando…
Combination of AFP vaccine and immune checkpoint inhibitors slows hepatocellular carcinoma progression in preclinical models
Many patients with hepatocellular carcinoma (HCC) do not respond to the first-line immune checkpoint inhibitor treatment. Immunization with effective cancer vaccines is an attractive alternative approach to immunotherapy. However, its efficacy remains insufficiently evaluated in preclinical studies....
Autores principales: | Lu, Xinjun, Deng, Shanshan, Xu, Jiejie, Green, Benjamin L., Zhang, Honghua, Cui, Guofei, Zhou, Yi, Zhang, Yi, Xu, Hongwei, Zhang, Fapeng, Mao, Rui, Zhong, Sheng, Cramer, Thorsten, Evert, Matthias, Calvisi, Diego F., He, Yukai, Liu, Chao, Chen, Xin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231990/ https://www.ncbi.nlm.nih.gov/pubmed/37040183 http://dx.doi.org/10.1172/JCI163291 |
Ejemplares similares
-
Preclinical Studies of the Off-Target Reactivity of AFP(158)-Specific TCR Engineered T Cells
por: Cai, Lun, et al.
Publicado: (2020) -
Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model
por: Dong, Mingjie, et al.
Publicado: (2018) -
Activated Wnt signaling promotes growth and progression of AFP-producing gastric cancer in preclinical models
por: Chen, Dongshao, et al.
Publicado: (2019) -
Development and Assessment of Nomogram Based on AFP Response for Patients with Unresectable Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors
por: Zhang, Yi, et al.
Publicado: (2023) -
β-Catenin signaling in hepatocellular carcinoma
por: Xu, Chuanrui, et al.
Publicado: (2022)